Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression

Lan Wang, Na Man, Xiao Jian Sun, Yurong Tan, Marta Garcia Cao, Fan Liu, Megan Hatlen, Haiming Xu, Gang Huang, Meredith Mattlin, Arpit Mehta, Evadnie Rampersaud, Robert Benezra, Stephen D Nimer

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Transcriptional regulators are recurrently altered through translocations, deletions, or aberrant expression in acute myeloid leukemia (AML). Although critically important in leukemogenesis, the underlying pathogenetic mechanisms they trigger remain largely unknown. Here, we identified that Id1 (inhibitor of DNA binding 1) plays a pivotal role in acute myeloid leukemogenesis. Using genetically modified mice, we found that loss of Id1 inhibited t(8;21) leukemia initiation and progression in vivo by abrogating protein kinase B (AKT)1 activation, and that Id1 interacted with AKT1 through its C terminus. An Id1 inhibitor impaired the in vitro growth of AML cells and, when combined with an AKT inhibitor, triggered even greater apoptosis and growth inhibition, whereas normal hematopoietic stem/progenitor cells were largely spared. We then performed in vivo experiments and found that the Id1 inhibitor significantly prolonged the survival of t(8;21)1 leukemic mice, whereas overexpression of activated AKT1 promoted leukemogenesis. Thus, our results establish Id1/Akt1 signaling as a potential therapeutic target in t(8;21) leukemia.

Original languageEnglish (US)
Pages (from-to)640-650
Number of pages11
JournalBlood
Volume126
Issue number5
DOIs
StatePublished - Jul 30 2015

Fingerprint

Leukemia
DNA
Hematopoietic Stem Cells
Acute Myeloid Leukemia
Proto-Oncogene Proteins c-akt
Myeloid Cells
Growth
Stem cells
Chemical activation
Apoptosis
Experiments
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression. / Wang, Lan; Man, Na; Sun, Xiao Jian; Tan, Yurong; Cao, Marta Garcia; Liu, Fan; Hatlen, Megan; Xu, Haiming; Huang, Gang; Mattlin, Meredith; Mehta, Arpit; Rampersaud, Evadnie; Benezra, Robert; Nimer, Stephen D.

In: Blood, Vol. 126, No. 5, 30.07.2015, p. 640-650.

Research output: Contribution to journalArticle

Wang, L, Man, N, Sun, XJ, Tan, Y, Cao, MG, Liu, F, Hatlen, M, Xu, H, Huang, G, Mattlin, M, Mehta, A, Rampersaud, E, Benezra, R & Nimer, SD 2015, 'Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression', Blood, vol. 126, no. 5, pp. 640-650. https://doi.org/10.1182/blood-2015-03-635532
Wang, Lan ; Man, Na ; Sun, Xiao Jian ; Tan, Yurong ; Cao, Marta Garcia ; Liu, Fan ; Hatlen, Megan ; Xu, Haiming ; Huang, Gang ; Mattlin, Meredith ; Mehta, Arpit ; Rampersaud, Evadnie ; Benezra, Robert ; Nimer, Stephen D. / Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression. In: Blood. 2015 ; Vol. 126, No. 5. pp. 640-650.
@article{734fc18bd0cc4402993e592332393050,
title = "Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression",
abstract = "Transcriptional regulators are recurrently altered through translocations, deletions, or aberrant expression in acute myeloid leukemia (AML). Although critically important in leukemogenesis, the underlying pathogenetic mechanisms they trigger remain largely unknown. Here, we identified that Id1 (inhibitor of DNA binding 1) plays a pivotal role in acute myeloid leukemogenesis. Using genetically modified mice, we found that loss of Id1 inhibited t(8;21) leukemia initiation and progression in vivo by abrogating protein kinase B (AKT)1 activation, and that Id1 interacted with AKT1 through its C terminus. An Id1 inhibitor impaired the in vitro growth of AML cells and, when combined with an AKT inhibitor, triggered even greater apoptosis and growth inhibition, whereas normal hematopoietic stem/progenitor cells were largely spared. We then performed in vivo experiments and found that the Id1 inhibitor significantly prolonged the survival of t(8;21)1 leukemic mice, whereas overexpression of activated AKT1 promoted leukemogenesis. Thus, our results establish Id1/Akt1 signaling as a potential therapeutic target in t(8;21) leukemia.",
author = "Lan Wang and Na Man and Sun, {Xiao Jian} and Yurong Tan and Cao, {Marta Garcia} and Fan Liu and Megan Hatlen and Haiming Xu and Gang Huang and Meredith Mattlin and Arpit Mehta and Evadnie Rampersaud and Robert Benezra and Nimer, {Stephen D}",
year = "2015",
month = "7",
day = "30",
doi = "10.1182/blood-2015-03-635532",
language = "English (US)",
volume = "126",
pages = "640--650",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression

AU - Wang, Lan

AU - Man, Na

AU - Sun, Xiao Jian

AU - Tan, Yurong

AU - Cao, Marta Garcia

AU - Liu, Fan

AU - Hatlen, Megan

AU - Xu, Haiming

AU - Huang, Gang

AU - Mattlin, Meredith

AU - Mehta, Arpit

AU - Rampersaud, Evadnie

AU - Benezra, Robert

AU - Nimer, Stephen D

PY - 2015/7/30

Y1 - 2015/7/30

N2 - Transcriptional regulators are recurrently altered through translocations, deletions, or aberrant expression in acute myeloid leukemia (AML). Although critically important in leukemogenesis, the underlying pathogenetic mechanisms they trigger remain largely unknown. Here, we identified that Id1 (inhibitor of DNA binding 1) plays a pivotal role in acute myeloid leukemogenesis. Using genetically modified mice, we found that loss of Id1 inhibited t(8;21) leukemia initiation and progression in vivo by abrogating protein kinase B (AKT)1 activation, and that Id1 interacted with AKT1 through its C terminus. An Id1 inhibitor impaired the in vitro growth of AML cells and, when combined with an AKT inhibitor, triggered even greater apoptosis and growth inhibition, whereas normal hematopoietic stem/progenitor cells were largely spared. We then performed in vivo experiments and found that the Id1 inhibitor significantly prolonged the survival of t(8;21)1 leukemic mice, whereas overexpression of activated AKT1 promoted leukemogenesis. Thus, our results establish Id1/Akt1 signaling as a potential therapeutic target in t(8;21) leukemia.

AB - Transcriptional regulators are recurrently altered through translocations, deletions, or aberrant expression in acute myeloid leukemia (AML). Although critically important in leukemogenesis, the underlying pathogenetic mechanisms they trigger remain largely unknown. Here, we identified that Id1 (inhibitor of DNA binding 1) plays a pivotal role in acute myeloid leukemogenesis. Using genetically modified mice, we found that loss of Id1 inhibited t(8;21) leukemia initiation and progression in vivo by abrogating protein kinase B (AKT)1 activation, and that Id1 interacted with AKT1 through its C terminus. An Id1 inhibitor impaired the in vitro growth of AML cells and, when combined with an AKT inhibitor, triggered even greater apoptosis and growth inhibition, whereas normal hematopoietic stem/progenitor cells were largely spared. We then performed in vivo experiments and found that the Id1 inhibitor significantly prolonged the survival of t(8;21)1 leukemic mice, whereas overexpression of activated AKT1 promoted leukemogenesis. Thus, our results establish Id1/Akt1 signaling as a potential therapeutic target in t(8;21) leukemia.

UR - http://www.scopus.com/inward/record.url?scp=84940042327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940042327&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-03-635532

DO - 10.1182/blood-2015-03-635532

M3 - Article

C2 - 26084673

AN - SCOPUS:84940042327

VL - 126

SP - 640

EP - 650

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -